Molecular Templates Q1 2024 GAAP EPS $0.08 Beats $(0.78) Estimate, Sales $11.09M Beat $5.90M Estimate

5/15/24 5:13:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MTEM alert in real time by email

Molecular Templates (NASDAQ:MTEM) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.78) by 110.26 percent. The company reported quarterly sales of $11.09 million which beat the analyst consensus estimate of $5.90 million by 87.99 percent. This is a 69.73 percent decrease over sales of $36.63 million the same period last year.

Get the next $MTEM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MTEM

Date	Price Target	Rating	Analyst

More analyst ratings

$MTEM
Leadership Updates

Live Leadership Updates

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer. Dr. Voi possesses more than 35 years of wide-ranging drug development experience. Dr. Voi will begin his new role on October 2, 2023. Dr. Voi joins MTEM from Novartis, where he served as Vice President, Global Program Head, for the PD-1 antibody Tislelizumab since April 2021. He was previously Global Program Head, Melanoma, at Novartis, a pos
9/28/23 4:11:00 PM ET
$MTEM
Biotechnology: Pharmaceutical Preparations
Health Care
Molecular Templates Strengthens Board of Directors and Management Team
Industry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General Counsel AUSTIN, Texas, March 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or "the Company"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the appointment of Gabriela Gruia, M.D., to its Board of Directors and the promotion of Megan Filoon to General Counsel. "Dr. Gruia brings a wealth of industry knowledge to our Board of Directors," said Barry Selick, Ph.D., Chairman of the Board of Molecular
3/2/22 8:00:00 AM ET
$MTEM
Biotechnology: Pharmaceutical Preparations
Health Care
Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors
NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders' established experience in global clinical development and especially with new technologies will be instrumental as we further advance our ongoing clinical trials and continue to expand our rare disease pipeline of novel therapeut
6/30/21 8:30:00 AM ET
$BGNE
$LEGN
$MTEM
$RARE
Biotechnology: Pharmaceutical Preparations
Health Care

$MTEM
Press Releases

Fastest customizable press release news feed in the world

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) programEarly indication of monotherapy activity in CTLA-4 ETB (MT-8421) program through T-reg depletion; no drug-related adverse events > grade 2Novel mechanism of action targeting CD38+ immune cells of B-cell, T-cell, and monocytic lineage representing enhanced potency in I&I without the need for conditioning therapy AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development o
8/14/24 4:21:00 PM ET
$MTEM
Biotechnology: Pharmaceutical Preparations
Health Care
Molecular Templates, Inc. Provides Interim Update
Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases. AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or "ETBs") for cancer and immune-mediated disease, today provided an update on its clinical-stage programs. Eric Poma, PhD., Chief Executive and Chief Scientific O
6/3/24 8:11:00 AM ET
$MTEM
Biotechnology: Pharmaceutical Preparations
Health Care
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ("ETBs"), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024. Recent Company Highlights MTEM presented clinical data at the 2024 AACR Annual Meeting that demonstrated MT-6402's tolerable safety and promising efficacy profile in relapsed/refractory HNSCC patients. As monotherapy in 7 evaluable HNSCC patient
5/15/24 5:11:54 PM ET
$MTEM
Biotechnology: Pharmaceutical Preparations
Health Care

Molecular Templates Q1 2024 GAAP EPS $0.08 Beats $(0.78) Estimate, Sales $11.09M Beat $5.90M Estimate

Chat with this insight

Recent Analyst Ratings for
$MTEM

$MTEM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Biotech Target N V sold $845,833 worth of shares (1,279,820 units at $0.66), closing all direct ownership in the company (SEC Form 4)

SEC Form 4 filed by Director Lalande Kevin M.

SEC Form 4 filed by Director Gruia Gabriela

$MTEM
Market Insights

Live Market Insights

Molecular Templates Provided An Update On Its Clinical-Stage Programs

Molecular Templates Q1 2024 GAAP EPS $0.08 Beats $(0.78) Estimate, Sales $11.09M Beat $5.90M Estimate

Molecular Templates Inc Files For Shelf Of Up To 11.01M Shares Of Common Stock By Selling Stockholders

$MTEM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BofA Securities initiated coverage on Molecular Templates with a new price target

UBS initiated coverage on Molecular Templates with a new price target

$MTEM
SEC Filings

SEC Form NT 10-Q filed by Molecular Templates Inc.

SEC Form DEF 14A filed by Molecular Templates Inc.

SEC Form PRE 14A filed by Molecular Templates Inc.

$MTEM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$MTEM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

Biotech Target N V bought $587,500 worth of shares (250,000 units at $2.35), increasing direct ownership by 24% to 1,279,820 units (SEC Form 4)

$MTEM
Leadership Updates

Live Leadership Updates

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

Molecular Templates Strengthens Board of Directors and Management Team

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

$MTEM
Press Releases

Fastest customizable press release news feed in the world

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

Molecular Templates, Inc. Provides Interim Update

Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update

Molecular Templates Q1 2024 GAAP EPS $0.08 Beats $(0.78) Estimate, Sales $11.09M Beat $5.90M Estimate

Chat with this insight

Recent Analyst Ratings for $MTEM

$MTEM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Biotech Target N V sold $845,833 worth of shares (1,279,820 units at $0.66), closing all direct ownership in the company (SEC Form 4)

SEC Form 4 filed by Director Lalande Kevin M.

SEC Form 4 filed by Director Gruia Gabriela

$MTEM Market Insights

Live Market Insights

Molecular Templates Provided An Update On Its Clinical-Stage Programs

Molecular Templates Q1 2024 GAAP EPS $0.08 Beats $(0.78) Estimate, Sales $11.09M Beat $5.90M Estimate

Molecular Templates Inc Files For Shelf Of Up To 11.01M Shares Of Common Stock By Selling Stockholders

$MTEM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BofA Securities initiated coverage on Molecular Templates with a new price target

UBS initiated coverage on Molecular Templates with a new price target

$MTEM SEC Filings

SEC Form NT 10-Q filed by Molecular Templates Inc.

SEC Form DEF 14A filed by Molecular Templates Inc.

SEC Form PRE 14A filed by Molecular Templates Inc.

$MTEM Large Ownership Changes

This live feed shows all institutional transactions in real time.

$MTEM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

Biotech Target N V bought $587,500 worth of shares (250,000 units at $2.35), increasing direct ownership by 24% to 1,279,820 units (SEC Form 4)

$MTEM Leadership Updates

Live Leadership Updates

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

Molecular Templates Strengthens Board of Directors and Management Team

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

$MTEM Press Releases

Fastest customizable press release news feed in the world

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

Molecular Templates, Inc. Provides Interim Update

Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update

Recent Analyst Ratings for
$MTEM

$MTEM
Insider Trading

$MTEM
Market Insights

$MTEM
Analyst Ratings

$MTEM
SEC Filings

$MTEM
Large Ownership Changes

$MTEM
Insider Purchases

$MTEM
Leadership Updates

$MTEM
Press Releases